Intellipharmaceutics Provides Operational Update
January 24, 2018 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Receipt of Nasdaq Notice
December 05, 2017 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
November 30, 2017 10:45 ET
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) and (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in...
Intellipharmaceutics Announces Closing of US$4 Million Financing
October 13, 2017 17:45 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces US$4 Million Registered Direct Offering
October 11, 2017 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Third Quarter 2017 Results
October 10, 2017 17:20 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
September 25, 2017 07:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Receipt of Nasdaq Notice
September 20, 2017 17:10 ET
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Operational Update
September 05, 2017 14:35 ET
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Appoints New Chief Financial Officer
September 01, 2017 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...